Lung and other thoracic tumours
Read more
New insights into the mechanism of acquired resistance to KRAS G12C inhibitors
Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required
Don't miss
-
Keynote lecture
8 November 2021, 13:45-14:15, Channel 1 -
Mini-Oral session
8 November 2021, 16:00-17:00, Channel 1 -
Gordon Peters lecture
9 November 2021, 13:45-14:15, Channel 1
PRECISION ONCOLOGY
Trials in precision oncology: current snapshot and future innovations
Increased use of molecular profiling is progressively improving decision-making processes in oncology compared with 20 years ago and helping to shape tomorrow’s clinical trials in targeted therapies
Study sheds light on lung adenocarcinoma-to-squamous transdifferentiation mechanism
AKT and EZH2 are identified as potential therapeutic targets to limit acquired resistance to osimertinib in patients with EGFR-mutated tumours of the lung
Next-generation sequencing of circulating tumour DNA can optimise clinical trial recruitment
Molecular pre-screening identified targetable alterations in patients with unknown genomic drivers
Pathogenic germline variants are more common than ‘incidental’
Tumour-only molecular profiling can spot hereditary cancer syndromes but resources are critical to make the most of this piece of information
How can exosome research improve patient management?
As the literature on exosomes continues to grow in cancer basic science, important questions remain regarding opportunities in the clinic
Healthcare budgets are still a main hurdle to global use of molecular testing for precision oncology
Topics
OPINIONS
Using ex vivo avatars to understand immune reactivation in cancer
Ton N Schumacher
CHIP clones in solid tumours: therapeutic targets or bystander phenomena?
Steffen Böttcher
Which immune cell type is it best to target therapeutically in brain tumours?
Johanna Joyce
